Zovact-TZ Injection is a potent combination antibiotic formulation containing Ceftriaxone 1000 mg and Tazobactam 125 mg, indicated for the treatment of a broad spectrum of bacterial infections. Ceftriaxone, a third-generation cephalosporin, exhibits bactericidal activity by inhibiting bacterial cell wall synthesis, while Tazobactam, a beta-lactamase inhibitor, enhances efficacy by preventing the degradation of Ceftriaxone by beta-lactamase producing organisms. This synergistic combination is effective against various Gram-positive and Gram-negative pathogens, including resistant strains. Zovact-TZ is commonly utilized in the management of severe infections such as lower respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections, septicemia, and bone and joint infections. The injection is administered intravenously or intramuscularly, with dosage and duration tailored according to the severity of infection and patient-specific factors. It is essential to perform susceptibility testing prior to therapy to ensure optimal outcomes. Caution is advised in patients with a history of hypersensitivity to beta-lactam antibiotics. Adverse effects may include hypersensitivity reactions, gastrointestinal disturbances, and local injection site reactions. Zovact-TZ Injection should be used under strict medical supervision to ensure safe and effective treatment.